Human Papillomavirus 16 E6 Antibodies in Individuals Without Diagnosed Cancer: A Pooled Analysis.
- Lang Kuhs, Krystle A
- Anantharaman, Devasena
- Waterboer, Tim
- Johansson, Mattias
- Brennan, Paul
- Michel, Angelika
- Willhauck-Fleckenstein, Martina
- Purdue, Mark P
- Holcatova, Ivana
- Ahrens, Wolfgang
- Lagiou, Pagona
- Polesel, Jerry
- Simonato, Lorenzo
- Merletti, Franco
- Healy, Claire M
- Kjaerheim, Kristina
- Conway, David I
- Macfarlane, Tatiana V
- Thomson, Peter
- Castellsague, Xavier
- Znaor, Ariana
- Black, Amanda
- Huang, Wen-Yi
- Krogh, Vittorio
- Trichopoulou, Antonia
- Bueno-de-Mesquita, H Bas
- Clavel-Chapelon, Francoise
- Weiderpass, Elisabete
- Ekström, Johanna
- Riboli, Elio
- Tjonneland, Anne
- Sanchez, Maria-Jose
- Travis, Ruth C
- Hildesheim, Allan
- Pawlita, Michael
- Kreimer, Aimee R
DOIAbstract
Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having i) moderate (mean fluorescent intensity [MFI]≥484 & <1000) or ii) high seroreactivity (MFI≥1000). Associations of moderate and high HPV16 E6 seroreactivity with i) demographic risk factors; and sero...
Add to ORKG